Mutations and polymorphisms in TP53 gene - An overview on the role in colorectal cancer

Mutagenesis

Volumn 27, Issue 2, 2012, Pages 211-218

  Naccarati, A ^a   Polakova, V ^a,b   Pardini, B ^a   Vodickova, L ^a,b,c   Hemminki, K ^d,e   Kumar, R ^d   Vodicka, P ^a,b  

^a INSTITUTE OF EXPERIMENTAL MEDICINE   (Czech Republic)

^b CHARLES UNIVERSITY   (Czech Republic)

^c NATIONAL INSTITUTE OF PUBLIC HEALTH   (Czech Republic)

^d GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^e LUND UNIVERSITY   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; CETUXIMAB; CYTOTOXIC AGENT; DNA; FLUOROURACIL; PROTEIN P53;

ARTICLE; CANCER PROGNOSIS; CANCER RISK; CANCER SURVIVAL; CANCER SUSCEPTIBILITY; CHEMORADIOTHERAPY; COLORECTAL CANCER; DNA DAMAGE; DNA POLYMORPHISM; ETHNICITY; GENE FREQUENCY; GENE MUTATION; GENE SEQUENCE; GENETIC ASSOCIATION; GENETIC PREDISPOSITION; GENETIC RISK; GENOTYPE; HAPLOTYPE; HUMAN; PHARMACOGENETICS; PREDICTIVE VALUE; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM; SOMATIC MUTATION; TREATMENT RESPONSE;

COLORECTAL NEOPLASMS; GENETIC PREDISPOSITION TO DISEASE; HUMANS; MUTATION; POLYMORPHISM, GENETIC; PROGNOSIS; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84863414654     PISSN: 02678357     EISSN: 14643804     Source Type: Journal    
DOI: 10.1093/mutage/ger067     Document Type: Article

References (106)

1. Lane, D. P. (1992) Cancer. p53, guardian of the genome. Nature, 358, 15-16.
2. Levine, A. J. (1997) p53, the cellular gatekeeper for growth and division. Cell, 88, 323-331. (Pubitemid 27131374)
3. Pietsch, E. C., Humbey, O. and Murphy, M. E. (2006) Polymorphisms in the p53 pathway. Oncogene, 25, 1602-1611.
4. Schuler, M. and Green, D. R. (2005) Transcription, apoptosis and p53: catch-22. Trends Genet., 21, 182-187.
5. Shaulsky, G., Ben-Ze'ev, A. and Rotter, V. (1990) Subcellular distribution of the p53 protein during the cell cycle of Balb/c 3T3 cells. Oncogene, 5, 1707-1711. (Pubitemid 120034693)
6. Meek, D. W. (2004) The p53 response to DNA damage. DNA Repair (Amst.), 3, 1049-1056. (Pubitemid 38997947)
7. Whibley, C., Pharoah, P. D. and Hollstein, M. (2009) p53 polymorphisms: cancer implications. Nat. Rev. Cancer, 9, 95-107.
8. Frebourg, T. and Friend, S. H. (1992) Cancer risks from germline p53 mutations. J. Clin. Invest., 90, 1637-1641.
9. George, B., Datar, R. H., Wu, L. et al. (2007) p53 gene and protein status: the role of p53 alterations in predicting outcome in patients with bladder cancer. J. Clin. Oncol., 25, 5352-5358. (Pubitemid 350232209)
10. Center, M. M., Jemal, A., Smith, R. A. and Ward, E. (2009) Worldwide variations in colorectal cancer. CA Cancer J. Clin., 59, 366-378.
11. Ferlay, J., Shin, H. R., Bray, F., Forman, D., Mathers, C. and Parkin, D. M. (2010) Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int. J. Cancer, 127, 2893-2917.
12. Fearon, E. R. and Vogelstein, B. (1990) A genetic model for colorectal tumorigenesis. Cell, 61, 759-767.
13. Gatenby, R. A. and Vincent, T. L. (2003) An evolutionary model of carcinogenesis. Cancer Res., 63, 6212-6220. (Pubitemid 37255166)
14. Worthley, D. L., Whitehall, V. L., Spring, K. J. and Leggett, B. A. (2007) Colorectal carcinogenesis: road maps to cancer. World J. Gastroenterol., 13, 3784-3791. (Pubitemid 47272303)
15. Soussi, T., Dehouche, K. and Beroud, C. (2000) p53 website and analysis of p53 gene mutations in human cancer: forging a link between epidemiology and carcinogenesis. Hum. Mutat., 15, 105-113. (Pubitemid 30036177)
16. Soussi, T. and Beroud, C. (2003) Significance of TP53 mutations in human cancer: a critical analysis of mutations at Cp G dinucleotides. Hum. Mutat., 21, 192-200. (Pubitemid 36292962)
17. Tominaga, T., Iwahashi, M., Takifuji, K. et al. (2010) Combination of p53 codon 72 polymorphism and inactive p53 mutation predicts chemosensitivity to 5-fluorouracil in colorectal cancer. Int. J. Cancer, 126, 1691-1701.
18. Vidaurreta, M., Maestro, M. L., Sanz-Casla, M. T., Rafael, S., Veganzones, S., de la Orden, V., Cerdan, J., Arroyo, M. and Torres, A. (2008) Colorectal carcinoma prognosis can be predicted by alterations in gene p53 exons 5 and 8. Int. J. Colorectal Dis., 23, 581-586.
19. Oki, E., Zhao, Y., Yoshida, R., Egashira, A., Ohgaki, K., Morita, M., Kakeji, Y. and Maehara, Y. (2009) The difference in p53 mutations between cancers of the upper and lower gastrointestinal tract. Digestion, 79 (Suppl. 1), 33-39.
20. Samowitz, W. S., Curtin, K., Ma, K. N., Edwards, S., Schaffer, D., Leppert, M. F. and Slattery, M. L. (2002) Prognostic significance of p53 mutations in colon cancer at the population level. Int. J. Cancer, 99,597-602. (Pubitemid 34461615)
21. Iacopetta, B., Russo, A., Bazan, V. et al. (2006) Functional categories of TP53 mutation in colorectal cancer: results of an International Collaborative Study. Ann. Oncol., 17, 842-847.
22. Lea, I. A., Jackson, M. A. and Dunnick, J. K. (2009) Genetic pathways to colorectal cancer. Mutat Res., 670, 96-98.
23. Bond, C. E., Umapathy, A.,Ramsnes, I. etal. (2011)P53 mutation is common in microsatellite stable, BRAF mutant colorectal cancers. Int. J. Cancer
24. Soussi, T. and Lozano, G. (2005) p53 mutation heterogeneity in cancer. Biochem. Biophys. Res. Commun., 331, 834-842. (Pubitemid 40615514)
25. Dumont, P., Leu, J. I., Della Pietra, A. C., 3rd, George, D. L. and Murphy, M. (2003) The codon 72 polymorphic variants of p53 have markedly different apoptotic potential. Nat. Genet., 33, 357-365. (Pubitemid 36278852)
26. Pim, D. and Banks, L. (2004) p53 polymorphic variants at codon 72 exert different effects on cell cycle progression. Int. J. Cancer, 108, 196-199. (Pubitemid 37541770)
27. Marin, M. C., Jost, C. A., Brooks, L. A. et al. (2000) A common polymorphism acts as an intragenic modifier of mutant p53 behaviour. Nat Genet., 25, 47-54. (Pubitemid 30257035)
28. Zhang, J., Zhuo, W. L., Zheng, Y. and Zhang, Y. S. (2010) Polymorphisms of TP53 codon 72 with prostate carcinoma risk: a meta-analysis. Med. Oncol., 27, 540-546.
29. Zhou, Y., Li, N., Zhuang, W., Liu, G. J., Wu, T. X., Yao, X., Du, L., Wei, M. L. and Wu, X. T. (2007) P53 codon 72 polymorphism and gastric cancer: a meta-analysis of the literature. Int. J. Cancer, 121, 1481-1486. (Pubitemid 47328706)
30. Dai, S., Mao, C., Jiang, L., Wang, G. and Cheng, H. (2009) P53 polymorphism and lung cancer susceptibility: a pooled analysis of 32 case-control studies. Hum. Genet., 125, 633-638.
31. Klug, S. J., Ressing, M., Koenig, J. et al. (2009) TP53 codon 72 polymorphism and cervical cancer: a pooled analysis of individual data from 49 studies. Lancet Oncol., 10, 772-784.
32. Bougeard, G., Baert-Desurmont, S., Tournier, I. etal. (2006) Impact of the MDM2 SNP309 and p53 Arg72Pro polymorphism on age oftumour onset in Li-Fraumeni syndrome. J. Med. Genet., 43, 531-533. (Pubitemid 43927330)
33. Beckman, G., Birgander, R., Sjalander, A., Saha, N., Holmberg, P. A., Kivela, A. and Beckman, L. (1994) Is p53 polymorphism maintained by natural selection? Hum. Hered., 44, 266-270. (Pubitemid 24229554)
34. Kashima, T., Makino, K., Soemantri, A. and Ishida, T. (2007) TP53 codon 72 polymorphism in 12 populations of insular Southeast Asia and Oceania. J. Hum. Genet., 52, 694-697. (Pubitemid 47106492)
35. Sucheston, L., Witonsky, D. B., Hastings, D., Yildiz, O., Clark, V. J., Di Rienzo, A. and Onel, K. (2011) Natural selection and functional genetic variation in the p53 pathway. Hum. Mol. Genet., 20, 1502-1508.
36. Song, H. R., Kweon, S. S., Kim, H. N. et al. (2011) p53 codon 72 polymorphism in patients with gastric and colorectal cancer in a Korean population. Gastric Cancer, 14, 242-247.
37. Joshi, A. M., Budhathoki, S., Ohnaka, K. et al. (2011) TP53 R72P and MDM2 SNP309 polymorphisms and colorectal cancer risk: the Fukuoka Colorectal Cancer Study. Jpn. J. Clin. Oncol., 41, 232-238.
38. Sameer, A. S., Shah, Z. A., Syeed, N., Banday, M. Z., Bashir, S. M., Bhat, B. A. and Siddiqi, M. A. (2010) TP53 Pro47Ser and Arg72Pro polymorphisms and colorectal cancer predisposition in an ethnic Kashmiri population. Genet. Mol. Res., 9, 651-660.
39. Cao, Z., Song, J. H., Park, Y. K., Maeng, E. J., Nam, S. W., Lee, J. Y. and Park, W. S. (2009) The p53 codon 72 polymorphism and susceptibility to colorectal cancer in Korean patients. Neoplasma, 56, 114-118.
40. Polakova, V., Pardini, B., Naccarati, A. et al. (2009) Genotype and haplotype analysis of cell cycle genes in sporadic colorectal cancer in the Czech Republic. Hum. Mutat., 30, 661-668.
41. Csejtei, A., Tibold, A., Varga, Z. et al. (2008) GSTM, GSTT and p53 polymorphisms as modifiers of clinical outcome in colorectal cancer. Anticancer Res., 28, 1917-1922. (Pubitemid 351892906)
42. Grunhage, F., Jungck, M., Lamberti, C. et al. (2008) Association of familial colorectal cancer with variants in the E-cadherin (CDH1) and cyclin D1 (CCND1) genes. Int. J. Colorectal Dis., 23, 147-154. (Pubitemid 350302510)
43. Dakouras,A.,Nikiteas,N.,Papadakis,E. etal. (2008)P53Arg72homozygosity and its increased incidence in left-sided sporadic colorectal adenocarcinomas, in a Greek-Caucasian population. Anticancer Res., 28, 1039-1043.
44. Mammano, E., Belluco, C., Bonafe, M. et al. (2009) Association of p53 polymorphisms and colorectal cancer: modulation of risk and progression. Eur. J. Surg. Oncol., 35, 415-419.
45. Tan, X. L., Nieters, A., Hoffmeister, M., Beckmann, L., Brenner, H. and Chang-Claude, J. (2007) Genetic polymorphisms in TP53, nonsteroidal anti-inflammatory drugs and the risk of colorectal cancer: evidence for gene-environment interaction? Pharmacogenet. Genomics, 17, 639-645. (Pubitemid 47057713)
46. Zhu, Z. Z., Wang, A. Z., Jia, H. R., Jin, X. X., He, X. L., Hou, L. F. and Zhu, G. (2007) Association of the TP53 codon 72 polymorphism with colorectal cancer in a Chinese population. Jpn. J. Clin. Oncol., 37,385-390. (Pubitemid 47248959)
47. Goodman, J. E., Mechanic, L. E., Luke, B. T., Ambs, S., Chanock, S. and Harris, C. C. (2006) Exploring SNP-SNP interactions and colon cancer risk using polymorphism interaction analysis. Int. J. Cancer, 118, 1790-1797. (Pubitemid 43376445)
48. Koushik, A., Tranah, G. J., Ma, J., Stampfer, M. J., Sesso, H. D., Fuchs, C. S., Giovannucci, E. L. and Hunter, D. J. (2006) p53 Arg72Pro polymorphism and risk of colorectal adenoma and cancer. Int. J. Cancer, 119, 1863-1868. (Pubitemid 44356844)
49. Perez, L. O., Abba, M. C., Dulout, F. N. and Golijow, C. D. (2006) Evaluation of p53 codon 72 polymorphism in adenocarcinomas of the colon and rectum in La Plata, Argentina. World J. Gastroenterol., 12, 1426-1429.
50. Perfumo, C., Bonelli, L., Menichini, P. et al. (2006) Increased risk of colorectal adenomas in Italian subjects carrying the p53 PIN3 A2-Pro72 haplotype. Digestion, 74, 228-235. (Pubitemid 46622794)
51. Kruger, S., Bier, A., Engel, C. et al. (2005) The p53 codon 72 variation is associated with the age of onset of hereditary non-polyposis colorectal cancer (HNPCC). J. Med. Genet., 42, 769-773. (Pubitemid 41475253)
52. Buyru, N., Tezol, A. and Dalay, N. (2005) p53 intronic G13964C variant in colon cancer and its association with HPV. Anticancer Res., 25, 2767-2769.
53. Sotamaa, K., Liyanarachchi, S., Mecklin, J. P., Jarvinen, H., Aaltonen, L. A., Peltomaki, P. and de la Chapelle, A. (2005) p53 codon 72 and MDM2 SNP309 polymorphisms and age of colorectal cancer onset in Lynch syndrome. Clin. Cancer Res., 11, 6840-6844. (Pubitemid 41428738)
54. Gemignani, F., Moreno, V., Landi, S. et al. (2004) A TP53 polymorphism is associated with increased risk of colorectal cancer and with reduced levels of TP53 m RNA. Oncogene, 23, 1954-1956. (Pubitemid 38445422)
55. Schneider-Stock, R., Boltze, C., Peters, B., Szibor, R., Landt, O., Meyer, F. and Roessner, A. (2004) Selective loss of codon 72 proline p53 and frequent mutational inactivation of the retained arginine allele in colorectal cancer. Neoplasia, 6, 529-535. (Pubitemid 39411089)
56. Sjalander, A., Birgander, R., Athlin, L., Stenling, R., Rutegard, J., Beckman, L. and Beckman, G. (1995) P53 germ line haplotypes associated with increased risk for colorectal cancer. Carcinogenesis, 16, 1461-1464.
57. Dahabreh, I. J., Linardou, H., Bouzika, P., Varvarigou, V. and Murray, S. (2010) TP53 Arg72Pro polymorphism and colorectal cancer risk: a systematic review and meta-analysis. Cancer Epidemiol. Biomarkers Prev., 19, 1840-1847.
58. Wang, J. J., Zheng, Y., Sun, L. et al. (2010) TP53 codon 72 polymorphism and colorectal cancer susceptibility: a meta-analysis. Mol. Biol. Rep.
59. Liu, L., Wang, K., Zhu, Z. M. and Shao, J. H. (2011) Associations between P53 Arg72Pro and development of digestive tract cancers: a meta-analysis. Arch. Med. Res., 42, 60-69.
60. Francisco, G., Menezes, P. R., Eluf-Neto, J. and Chammas, R. (2011) Arg72Pro TP53 polymorphism and cancer susceptibility: a comprehensive meta-analysis of 302 case-control studies. Int. J. Cancer, 129, 920-930.
61. Wu, X., Zhao, H., Amos, C. I., Shete, S., Makan, N., Hong, W. K., Kadlubar, F. F. and Spitz, M. R. (2002) p.53 genotypes and haplotypes associated with lung cancer susceptibility and Ethnicity. J. Natl. Cancer Inst., 94, 681-690. (Pubitemid 34552489)
62. Runnebaum, I. B., Tong, X. W., Konig, R., Zhao, H., Korner, K., Atkinson, E. N., Kreienberg, R., Kieback, D. G. and Hong, Z. (1995) p53-based blood test for p53PIN3 and risk for sporadic ovarian cancer. Lancet, 345, 994.
63. Weston, A. and Godbold, J. H. (1997) Polymorphisms of H-ras-1 and p.53 in breast cancer and lung cancer: a meta-analysis. Environ. Health Perspect., 105 (Suppl. 4), 919-926.
64. Wang-Gohrke, S., Weikel, W.,Risch, H. etal. (1999) Intron variants of the p53 gene are associated with increased risk for ovarian cancer but not in carriers of BRCA1 or BRCA2 germline mutations. Br. J. Cancer, 81, 179-183. (Pubitemid 29415510)
65. Powell, B. L., van Staveren, I. L., Roosken, P., Grieu, F., Berns, E. M. and Iacopetta, B. (2002) Associations between common polymorphisms in TP53 and p21WAF1/Cip1 and phenotypic features of breast cancer. Carcinogenesis, 23, 311-315. (Pubitemid 34224008)
66. Khaliq, S., Hameed, A., Khaliq, T., Ayub, Q., Qamar, R., Mohyuddin, A., Mazhar, K. and Qasim-Mehdi, S. (2000) P53 mutations, polymorphisms, and haplotypes in Pakistani ethnic groups and breast cancer patients. Genet. Test., 4, 23-29. (Pubitemid 30217737)
67. Mitra, S., Misra, C., Singh, R. K., Panda, C. K. and Roychoudhury, S. (2005) Association of specific genotype and haplotype of p53 gene with cervical cancer in India. J. Clin. Pathol., 58, 26-31. (Pubitemid 40070492)
68. International Hap Map Consortium (2005) A haplotype map of the human genome. Nature, 437, 1299-1320.
69. Gast, A., Bermejo, J. L., Flohr, T., Stanulla, M., Burwinkel, B., Schrappe, M., Bartram, C. R., Hemminki, K. and Kumar, R. (2007) Folate metabolic gene polymorphisms and childhood acute lymphoblastic leukemia: a case-control study. Leukemia, 21, 320-325. (Pubitemid 46158126)
70. Bellini, I., Pitto, L., Marini, M. G. et al. (2010) Delta N133p53 expression levels in relation to haplotypes of the TP53 internal promoter region. Hum. Mutat., 31, 456-465.
71. Munro, A. J.,Lain, S. and Lane, D. P. (2005) P53 abnormalities and outcomes in colorectal cancer: a systematic review. Br. J. Cancer, 92,434-444. (Pubitemid 40395523)
72. Roth, J. A. (1999) p53 prognostication: paradigm or paradox? Clin. Cancer Res., 5, 3345.
73. Hoff, P. M. (2005) Is there a role for routine p53 testing in colorectal cancer? J. Clin. Oncol., 23, 7395-7396. (Pubitemid 46291798)
74. Robles, A. I. and Harris, C. C. (2010) Clinical outcomes and correlates of TP53 mutations and cancer. Cold Spring Harb. Perspect. Biol., 2, a001016.
75. Millau, J. F., Bastien, N. and Drouin, R. (2009) P53 transcriptional activities: a general overview and some thoughts. Mutat. Res., 681, 118-133.
76. Vogelstein, B. and Kinzler, K. W. (2004) Cancer genes and the pathways they control. Nat. Med., 10, 789-799. (Pubitemid 39070849)
77. Berns, E. M., Foekens, J. A., Vossen, R. et al. (2000) Complete sequencing of TP53 predicts poor response to systemic therapy of advanced breast cancer. Cancer Res., 60, 2155-2162. (Pubitemid 30225178)
78. Migliavacca, M., Ottini, L., Bazan, V. etal. (2004) TP53 in gastric cancer: mutations in the l3 loop and LSH motif DNA-binding domains of TP53 predict poor outcome. J. Cell Physiol., 200, 476-485. (Pubitemid 39006940)
79. Young, K. H., Weisenburger, D. D., Dave, B. J. etal. (2007) Mutations in the DNA-binding codons of TP53, which are associated with decreased expression of TRAILreceptor-2, predict for poor survival in diffuse large B-cell lymphoma. Blood, 110, 4396-4405. (Pubitemid 351377806)
80. Poeta, M. L., Manola, J., Goldwasser, M. A. et al. (2007) TP53 mutations and survival in squamous-cell carcinoma of the head and neck. N. Engl. J. Med., 357, 2552-2561. (Pubitemid 350294222)
81. Petitjean, A., Achatz, M. I., Borresen-Dale, A. L., Hainaut, P. and Olivier, M. (2007) TP53 mutations in human cancers: functional selection and impact on cancer prognosis and outcomes. Oncogene, 26, 2157-2165. (Pubitemid 46536647)
82. Takahashi, S., Moriya, T., Ishida, T., Shibata, H., Sasano, H., Ohuchi, N. and Ishioka, C. (2008) Prediction of breast cancer prognosis by gene expression profile of TP53 status. Cancer Sci., 99, 324-332. (Pubitemid 351228487)
83. Bergamaschi, D., Gasco, M., Hiller, L. et al. (2003) p53 polymorphism influences response in cancer chemotherapy via modulation of p73-dependent apoptosis. Cancer Cell, 3, 387-402. (Pubitemid 38340307)
84. Sullivan, A., Syed, N., Gasco, M. etal. (2004) Polymorphism in wild-type p.53 modulates response to chemotherapy in vitro and in vivo. Oncogene, 23, 3328-3337. (Pubitemid 38669822)
85. Nelson, H. H., Wilkojmen, M., Marsit, C. J. and Kelsey, K. T. (2005) TP53 mutation, allelism and survival in non-small cell lung cancer. Carcinogenesis, 26, 1770-1773. (Pubitemid 41487993)
86. Tommiska, J., Eerola, H., Heinonen, M. et al. (2005) Breast cancer patients with p53 Pro72 homozygous genotype have a poorer survival. Clin. Cancer Res., 11, 5098-5103. (Pubitemid 41003693)
87. Xu, Y., Yao, L., Ouyang, T., Li, J., Wang, T., Fan, Z., Lin, B., Lu, Y. and Xie, Y. (2005) p53 Codon 72 polymorphism predicts the pathologic response to neoadjuvant chemotherapy in patients with breast cancer. Clin. Cancer Res., 11, 7328-7333. (Pubitemid 41507691)
88. Royds, J. A. and Iacopetta, B. (2006) p53 and disease: when the guardian angel fails. Cell Death Differ., 13, 1017-1026.
89. Russo, A., Bazan, V., Iacopetta, B., Kerr, D., Soussi, T. and Gebbia, N. (2005) The TP53 colorectal cancer international collaborative study on the prognostic and predictive significance of p53 mutation: influence of tumor site, type of mutation, and adjuvant treatment. J. Clin. Oncol., 23, 7518-7528. (Pubitemid 46291815)
90. Bazan, V., Agnese, V., Corsale, S. et al. (2005) Specific TP53 and/or Ki-ras mutations as independent predictors of clinical outcome in sporadic colorectal adenocarcinomas: results of a 5-year Gruppo Oncologico dell'Italia Meridionale (GOIM) prospective study. Ann. Oncol., 16 (Suppl. 4), iv50-iv55. (Pubitemid 43084946)
91. Mollevi, D. G., Serrano, T., Ginesta, M. M. et al. (2007) Mutations in TP53 are a prognostic factor in colorectal hepatic metastases undergoing surgical resection. Carcinogenesis, 28, 1241-1246. (Pubitemid 47062683)
92. Berg M., Danielsen, S. A., Ahlquist, T. et al. (2010) DNA sequence profiles of the colorectal cancer critical gene set KRAS-BRAF-PIK3CA-PTEN-TP53 related to age at disease onset. PLo S One 5, e13978.
93. Cleven, A. H., Wouters, B. G., Schutte, B., Spiertz, A. J., van Engeland, M. and de Bruine, A. P. (2008) Poorer outcome in stromal HIF-2 alpha- and CA9-positive colorectal adenocarcinomas is associated with wild-type TP53 but not with BNIP3 promoter hypermethylation or apoptosis. Br. J. Cancer, 99, 727-733.
94. Rao, B., Gao, Y., Huang, J. et al. (2011) Mutations of p53 and K-ras correlate TF expression in human colorectal carcinomas: TF down-regulation as a marker of poor prognosis. Int. J. Colorectal Dis., 26, 593-601.
95. Westra, J. L., Schaapveld, M., Hollema, H. et al. (2005) Determination of TP53 mutation is more relevant than microsatellite instability status for the prediction of disease-free survival in adjuvant-treated stage III colon cancer patients. J. Clin. Oncol., 23, 5635-5643.
96. Katkoori, V. R., Jia, X., Chatla, C., Kumar, S., Ponnazhagan, S., Callens, T., Messiaen, L., Grizzle, W. E. and Manne, U. (2008) Clinical significance of a novel single nucleotide polymorphism in the 5' untranslated region of the Rabphillin-3A-Like gene in colorectal adenocarcinoma. Front. Biosci., 13, 1050-1061. (Pubitemid 351594746)
97. Gudkov, A. V. and Komarova, E. A. (2003) The role of p53 in determining sensitivity to radiotherapy. Nat. Rev. Cancer, 3, 117-129. (Pubitemid 37328879)
98. Longley, D. B., Harkin, D. P. and Johnston, P. G. (2003) 5-Fluorouracil: mechanisms of action and clinical strategies. Nat. Rev. Cancer, 3, 330-338. (Pubitemid 37328853)
99. Ahnen, D. J., Feigl, P., Quan, G. et al. (1998) Ki-ras mutation and p53 overexpression predict the clinical behavior of colorectal cancer: a Southwest Oncology Group study. Cancer Res., 58, 1149-1158. (Pubitemid 28183202)
100. Elsaleh, H., Powell, B., Mc Caul, K., Grieu, F., Grant, R., Joseph, D. and Iacopetta, B. (2001) P53 alteration and microsatellite instability have predictive value for survival benefit from chemotherapy in stage III colorectal carcinoma. Clin. Cancer Res., 7, 1343-1349. (Pubitemid 32708690)
101. Liang, J. T., Huang, K. C., Cheng, Y. M., Hsu, H. C., Cheng, A. L., Hsu, C. H., Yeh, K. H., Wang, S. M. and Chang, K. J. (2002) P53 overexpression predicts poor chemosensitivity to high-dose 5-fluorouracil plus leucovorin chemotherapy for stage IV colorectal cancers after palliative bowel resection. Int. J. Cancer, 97, 451-457.
102. Oden-Gangloff, A., Di Fiore, F., Bibeau, F. et al. (2009) TP53 mutations predict disease control in metastatic colorectal cancer treated with cetuximab-based chemotherapy. Br. J. Cancer, 100, 1330-1335.
103. Ince, W. L., Jubb, A. M., Holden, S. N. et al. (2005) Association ofk-ras, b-raf, and p.53 status with the treatment effect of bevacizumab. J. Natl. Cancer Inst., 97, 981-989. (Pubitemid 41430564)
104. Etienne-Grimaldi, M. C., Formento, J. L., Francoual, M. et al. (2008) K-Ras mutations and treatment outcome in colorectal cancer patients receiving exclusive fluoropyrimidine therapy. Clin. Cancer Res., 14, 4830-4835.
105. Vazquez, A., Bond, E. E., Levine, A. J. and Bond, G. L. (2008) The genetics of the p53 pathway, apoptosis and cancer therapy. Nat. Rev. Drug Discov., 7, 979-987.
106. Olivier, M., Petitjean, A., Marcel, V., Petre, A., Mounawar, M., Plymoth, A., de Fromentel, C. C. and Hainaut, P. (2009) Recent advances in p53 research: an interdisciplinary perspective. Cancer Gene Ther., 16, 1-12.